ERBB2 and breast cancer: Moreover, neratinib was previously shown to induce HSP90 dissociation with HER2 leading to its ubiquitylation and endocytic degradation in HER2 positive breast cancer cells, providing an insight into a new mechanism of action in addition to the inhibition of HER receptor activation and downstream signal transduction [25].